Maravai Lifesciences Holdings (MRVI) Operating Expenses (2020 - 2026)

Maravai Lifesciences Holdings' Operating Expenses history runs 7 years deep, the most recent figure standing at $35.9 million for Q1 2026.

• On a quarterly basis, Operating Expenses fell 36.96% year-over-year to $35.9 million in Q1 2026; TTM through Mar 2026 was $267.9 million, a 32.13% decrease from a year earlier, with the FY2025 full-year figure at $249.3 million, down 27.53% from the prior year.
• Operating Expenses eased to $35.9 million in Q1 2026 per MRVI's latest filing, from $71.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $197.8 million in Q3 2024 and bottomed at -$67.5 million in Q4 2023.
• The 5-year median for Operating Expenses is $76.5 million (2023), against an average of $72.1 million.
• Across the five-year window, Operating Expenses sank 170.65% in 2023 and soared 184.64% in 2024, its largest moves.
• Year by year, Operating Expenses stood at $95.5 million in 2022, then plunged by 170.65% to -$67.5 million in 2023, then surged by 184.64% to $57.1 million in 2024, then increased by 25.48% to $71.6 million in 2025, then slumped by 49.94% to $35.9 million in 2026.
• Per Business Quant, the three latest MRVI Operating Expenses figures stand at $35.9 million (Q1 2026), $71.6 million (Q4 2025), and $46.7 million (Q3 2025).